| MeSH term | MeSH ID | Detail |
|---|---|---|
| Abnormalities, Drug-Induced | D000014 | 10 associated lipids |
| Abortion, Spontaneous | D000022 | 12 associated lipids |
| Abscess | D000038 | 13 associated lipids |
| Achondroplasia | D000130 | 1 associated lipids |
| Acinetobacter Infections | D000151 | 4 associated lipids |
| Acne Vulgaris | D000152 | 35 associated lipids |
| Acquired Immunodeficiency Syndrome | D000163 | 12 associated lipids |
| Actinomycetales Infections | D000193 | 4 associated lipids |
| Agammaglobulinemia | D000361 | 4 associated lipids |
| Airway Obstruction | D000402 | 13 associated lipids |
Azithramycine
Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.
Cross Reference
Introduction
To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Azithramycine?
Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (156)
- Clin. Infect. Dis. (64)
- J. Antimicrob. Chemother. (50)
- Others (435)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Azithramycine
PubChem Associated disorders and diseases
What pathways are associated with Azithramycine
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Azithramycine?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (66)
- J. Antimicrob. Chemother. (25)
- Clin. Infect. Dis. (13)
- Others (151)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with Azithramycine?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Azithramycine?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with Azithramycine?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (44)
- J. Antimicrob. Chemother. (18)
- Clin. Infect. Dis. (10)
- Others (126)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Azithramycine?
Mouse Model
Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).
Knock-out
Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).
Tissue Model
Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with Azithramycine
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Gordillo ME et al. | In vitro activity of azithromycin against bacterial enteric pathogens. | 1993 | Antimicrob. Agents Chemother. | pmid:8390813 |
| Bonnet M and Van der Auwera P | Preincubation of Haemophilus influenzae with subinhibitory concentrations of macrolides: influence on human neutrophil chemiluminescence. | 1993 | Antimicrob. Agents Chemother. | pmid:8390808 |
| Minguez F et al. | In vitro killing kinetics and postantibiotic effect of josamycin and other macrolides on several bacteria. | 1993 May-Jun | Chemotherapy | pmid:8389685 |
| Melski JW et al. | Primary and secondary erythema migrans in central Wisconsin. | 1993 | Arch Dermatol | pmid:8389536 |
| Hammerschlag MR et al. | Single dose of azithromycin for the treatment of genital chlamydial infections in adolescents. | 1993 | J. Pediatr. | pmid:8388950 |
| Cameron DJ | Effectiveness of early Lyme disease treatment. | 1993 | Am. J. Med. | pmid:8388627 |
| Brown ST et al. | Azithromycin, rifabutin, and rifapentine for treatment and prophylaxis of Mycobacterium avium complex in rats treated with cyclosporine. | 1993 | Antimicrob. Agents Chemother. | pmid:8384809 |
| Vaara M | Outer membrane permeability barrier to azithromycin, clarithromycin, and roxithromycin in gram-negative enteric bacteria. | 1993 | Antimicrob. Agents Chemother. | pmid:8383945 |
| Nahata MC et al. | Pharmacokinetics of azithromycin in pediatric patients after oral administration of multiple doses of suspension. | 1993 | Antimicrob. Agents Chemother. | pmid:8383944 |
| Spangler SK and Appelbaum PC | Oxyrase, a method which avoids CO2 in the incubation atmosphere for anaerobic susceptibility testing of antibiotics affected by CO2. | 1993 | J. Clin. Microbiol. | pmid:8381817 |
| Holdcroft C | Two new macrolide antibiotics: clarithromycin and azithromycin. | 1993 | Nurse Pract | pmid:8380492 |
| Odugbemi T et al. | Single oral dose of azithromycin for therapy of susceptible sexually transmitted diseases: a multicenter open evaluation. | 1993 Jul-Sep | West Afr J Med | pmid:8312208 |
| Berger BW | Lyme disease. | 1993 | Semin Dermatol | pmid:8312152 |
| O'Connell S et al. | Chronic active toxoplasmosis in an immunocompetent patient. | 1993 | J. Infect. | pmid:8308325 |
| Godofsky EW | Treatment of presumed cerebral toxoplasmosis with azithromycin. | 1994 | N. Engl. J. Med. | pmid:8302335 |
| Lalak NJ and Morris DL | Azithromycin clinical pharmacokinetics. | 1993 | Clin Pharmacokinet | pmid:8287632 |
| Meyer AP et al. | Uptake of azithromycin by human monocytes and enhanced intracellular antibacterial activity against Staphylococcus aureus. | 1993 | Antimicrob. Agents Chemother. | pmid:8285612 |
| Donowitz GR and Earnhardt KI | Azithromycin inhibition of intracellular Legionella micdadei. | 1993 | Antimicrob. Agents Chemother. | pmid:8285604 |
| Gage TW | New drugs from 1991-1992. | 1993 | Tex Dent J | pmid:8273018 |
| Pajukanta R | In vitro antimicrobial susceptibility of Porphyromonas gingivalis to azithromycin, a novel macrolide. | 1993 | Oral Microbiol. Immunol. | pmid:8265209 |
| Saverino D et al. | Plasmid loss from gram-negative bacteria exposed to subinhibitory concentrations of beta-lactam drugs and azithromycin. | 1993 | New Microbiol. | pmid:8264424 |
| de Górgolas Hernández-Mora M et al. | [Therapeutic approaches to cryptosporidiosis. A review of the literature]. | 1993 | Rev Clin Esp | pmid:8259458 |
| Fass RJ | Erythromycin, clarithromycin, and azithromycin: use of frequency distribution curves, scattergrams, and regression analyses to compare in vitro activities and describe cross-resistance. | 1993 | Antimicrob. Agents Chemother. | pmid:8257127 |
| Cantin L and Chamberland S | In vitro evaluation of the activities of azithromycin alone and combined with pyrimethamine against Toxoplasma gondii. | 1993 | Antimicrob. Agents Chemother. | pmid:8239619 |
| Tomazic J et al. | In vivo administration of azithromycin affects lymphocyte activity in vitro. | 1993 | Antimicrob. Agents Chemother. | pmid:8239585 |
| Agacfidan A et al. | In vitro activity of azithromycin (CP-62,993) against Chlamydia trachomatis and Chlamydia pneumoniae. | 1993 | Antimicrob. Agents Chemother. | pmid:8239579 |
| Lefèvre JC et al. | In vitro evaluation of activities of azithromycin, clarithromycin and sparfloxacin against Chlamydia trachomatis. | 1993 | Pathol. Biol. | pmid:8233628 |
| Weiss LM et al. | Efficacy of azithromycin for treating Babesia microti infection in the hamster model. | 1993 | J. Infect. Dis. | pmid:8228366 |
| Braga PC and Piatti G | Interference by subinhibitory concentrations of azithromycin with the mechanism of bacterial adhesion to human epithelial cells. | 1993 Nov-Dec | Chemotherapy | pmid:8222872 |
| Scaglione F et al. | A new model examining intracellular and extracellular activity of amoxicillin, azithromycin, and clarithromycin in infected cells. | 1993 Nov-Dec | Chemotherapy | pmid:8222870 |
| Dever LL et al. | Comparative in vitro activities of clarithromycin, azithromycin, and erythromycin against Borrelia burgdorferi. | 1993 | Antimicrob. Agents Chemother. | pmid:8215288 |
| Blais J et al. | Inhibition of Toxoplasma gondii protein synthesis by azithromycin. | 1993 | Antimicrob. Agents Chemother. | pmid:8215287 |
| Benson CA | Treatment of disseminated disease due to the Mycobacterium avium complex in patients with AIDS. | 1994 | Clin. Infect. Dis. | pmid:8204776 |
| Marchi M et al. | [Azithromycin-omeprazole. Treatment for the eradication of Helicobacter pylori]. | 1994 | Minerva Gastroenterol Dietol | pmid:8204705 |
| Mizukane R et al. | Comparative in vitro exoenzyme-suppressing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa. | 1994 | Antimicrob. Agents Chemother. | pmid:8203850 |
| Stamler DA et al. | Azithromycin pharmacokinetics and intracellular concentrations in Legionella pneumophila-infected and uninfected guinea pigs and their alveolar macrophages. | 1994 | Antimicrob. Agents Chemother. | pmid:8192446 |
| Spangler SK et al. | Effect of CO2 on susceptibilities of anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin. | 1994 | Antimicrob. Agents Chemother. | pmid:8192445 |
| Kelsey JJ et al. | Presence of azithromycin breast milk concentrations: a case report. | 1994 | Am. J. Obstet. Gynecol. | pmid:8178871 |
| Bosatra A et al. | [Effectiveness of and tolerance to azithromycin versus roxithromycin in the treatment of patients with acute infections of the upper respiratory tract]. | 1994 | Clin Ter | pmid:8168348 |
| Bermudez LE et al. | Recombinant granulocyte-macrophage colony-stimulating factor enhances the effects of antibiotics against Mycobacterium avium complex infection in the beige mouse model. | 1994 | J. Infect. Dis. | pmid:8158029 |
| Pfefferkorn ER and Borotz SE | Comparison of mutants of Toxoplasma gondii selected for resistance to azithromycin, spiramycin, or clindamycin. | 1994 | Antimicrob. Agents Chemother. | pmid:8141576 |
| SteingrÃmsson O et al. | Single dose azithromycin treatment of gonorrhea and infections caused by C. trachomatis and U. urealyticum in men. | 1994 Jan-Feb | Sex Transm Dis | pmid:8140488 |
| DÃaz Sánchez M et al. | [New medications: azithromycin]. | 1993 Jul-Sep | Rev Med Univ Navarra | pmid:8134755 |
| Weber K et al. | Azithromycin versus penicillin V for the treatment of early Lyme borreliosis. | 1993 Nov-Dec | Infection | pmid:8132365 |
| Kanatani MS and Guglielmo BJ | The new macrolides. Azithromycin and clarithromycin. | 1994 | West. J. Med. | pmid:8128699 |
| Rodriguez WJ and Wiedermann BL | The role of newer oral cephalosporins, fluoroquinolones, and macrolides in the treatment of pediatric infections. | 1994 | Adv Pediatr Infect Dis | pmid:8123221 |
| Saba J et al. | Pyrimethamine plus azithromycin for treatment of acute toxoplasmic encephalitis in patients with AIDS. | 1993 | Eur. J. Clin. Microbiol. Infect. Dis. | pmid:8112357 |
| Parent M | [Initial empiric treatment of pneumonia and the new antibiotics]. | 1994 | Union Med Can | pmid:8109061 |
| Bailey RL et al. | Randomised controlled trial of single-dose azithromycin in treatment of trachoma. | 1993 | Lancet | pmid:8102427 |
| Wynn RF et al. | Azithromycin for cerebral toxoplasmosis in AIDS. | 1993 | Lancet | pmid:8093526 |